Total Payments
$114,500
2024 Payments
$3,108
Companies
80
Transactions
2,495
Medicare Patients
4,932
Medicare Billing
$641,298
Payment Breakdown by Category
Other$45,645 (39.9%)
Food & Beverage$44,842 (39.2%)
Research$17,337 (15.1%)
Travel$3,600 (3.1%)
Consulting$2,775 (2.4%)
Education$301.69 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,645 | 44 | 39.9% |
| Food and Beverage | $44,842 | 2,416 | 39.2% |
| Unspecified | $17,337 | 6 | 15.1% |
| Travel and Lodging | $3,600 | 22 | 3.1% |
| Consulting Fee | $2,775 | 2 | 2.4% |
| Education | $301.69 | 5 | 0.3% |
Payments by Type
General
$97,164
2,489 transactions
Research
$17,337
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $17,337 | 6 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $14,944 | 160 | $0 (2022) |
| Allergan, Inc. | $13,892 | 133 | $0 (2021) |
| ABBVIE INC. | $13,289 | 138 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $12,908 | 156 | $0 (2022) |
| SK Life Science, Inc. | $3,554 | 35 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $2,789 | 160 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $2,776 | 25 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,427 | 147 | $0 (2024) |
| UCB, Inc. | $2,255 | 145 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,108 | 127 | ABBVIE INC. ($302.30) |
| 2023 | $5,450 | 270 | AbbVie Inc. ($427.92) |
| 2022 | $13,486 | 394 | ABBVIE INC. ($4,638) |
| 2021 | $19,870 | 473 | AbbVie Inc. ($7,845) |
| 2020 | $12,390 | 353 | Allergan, Inc. ($7,527) |
| 2019 | $7,921 | 284 | Sunovion Pharmaceuticals Inc. ($3,046) |
| 2018 | $34,526 | 291 | Eli Lilly and Company ($16,044) |
| 2017 | $17,748 | 303 | Sunovion Pharmaceuticals Inc. ($6,654) |
All Payment Transactions
2,495 individual payment records from CMS Open Payments — Page 1 of 100
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: NEUROLOGY | ||||||
| 12/17/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Neurology | ||||||
| 12/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: PAIN | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Immunology | ||||||
| 12/05/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $30.81 | General |
| 12/05/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: AMANTADINE | ||||||
| 12/03/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.79 | General |
| Category: Neuroscience | ||||||
| 12/02/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: Neurology | ||||||
| 11/19/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: Neurology | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $30.55 | General |
| Category: Rare Disease | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $122.45 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Neuroscience | ||||||
| 11/08/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: Neurology | ||||||
| 11/06/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $11.61 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/02/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $32.20 | General |
| 10/30/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Neurology | ||||||
| 10/29/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $39.76 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $109.19 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Neurology | ||||||
| 10/23/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $34.14 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $15,116 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,478 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $388.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,184 | 1,352 | $450,810 | $157,932 |
| 2022 | 19 | 1,176 | 1,357 | $418,752 | $153,888 |
| 2021 | 22 | 1,200 | 1,410 | $406,667 | $156,034 |
| 2020 | 18 | 1,372 | 1,781 | $477,403 | $173,444 |
Total Patients
4,932
Total Services
5,900
Medicare Billing
$641,298
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 203 | 205 | $83,025 | $26,869 | 32.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 118 | 151 | $55,115 | $19,686 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 208 | $53,040 | $19,304 | 36.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 53 | 55 | $51,150 | $17,482 | 34.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 123 | 190 | $45,515 | $17,430 | 38.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 90 | 90 | $40,050 | $13,984 | 34.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 71 | 71 | $19,880 | $6,537 | 32.9% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 36 | 36 | $16,920 | $5,862 | 34.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 64 | 67 | $13,315 | $4,998 | 37.5% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 41 | 41 | $11,070 | $4,155 | 37.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 59 | $10,620 | $3,941 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $10,050 | $3,630 | 36.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 53 | $8,420 | $3,255 | 38.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 19 | 20 | $11,300 | $3,239 | 28.7% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 16 | 16 | $8,720 | $3,052 | 35.0% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 11 | 11 | $6,985 | $2,424 | 34.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 49 | 49 | $5,635 | $2,087 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 184 | 276 | $65,420 | $24,236 | 37.0% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 55 | 56 | $52,080 | $18,745 | 36.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 118 | 120 | $48,600 | $18,070 | 37.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 104 | 118 | $40,745 | $15,946 | 39.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 102 | 151 | $30,955 | $12,120 | 39.2% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 88 | 89 | $33,690 | $11,995 | 35.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 70 | 70 | $30,280 | $10,792 | 35.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 64 | 64 | $21,440 | $7,371 | 34.4% |
About Dr. Vikram Atit, MD
Dr. Vikram Atit, MD is a Neurology healthcare provider based in Holiday, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871560904.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vikram Atit, MD has received a total of $114,500 in payments from pharmaceutical and medical device companies, with $3,108 received in 2024. These payments were reported across 2,495 transactions from 80 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($45,645).
As a Medicare-enrolled provider, Atit has provided services to 4,932 Medicare beneficiaries, totaling 5,900 services with total Medicare billing of $641,298. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Holiday, FL
- Active Since 03/07/2006
- Last Updated 12/16/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1871560904
Products in Payments
- UBRELVY (Drug) $19,311
- APTIOM (Drug) $14,743
- TROKENDI XR (Drug) $12,439
- NAMZARIC (Drug) $3,926
- NURTEC ODT (Drug) $3,676
- XCOPRI (Drug) $2,972
- QULIPTA (Drug) $2,619
- Aimovig (Biological) $1,928
- INGREZZA (Drug) $1,424
- ZEPOSIA (Drug) $1,224
- NUEDEXTA (Drug) $1,212
- GOCOVRI (Drug) $1,043
- AUSTEDO (Drug) $1,001
- Hizentra (Biological) $990.84
- Fycompa (Drug) $968.97
- RYTARY (Drug) $962.36
- Neupro (Drug) $838.67
- KESIMPTA (Drug) $824.92
- Briviact (Drug) $730.96
- PANZYGA (Biological) $730.75
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.